Clinical trials: SARS-CoV2
Sars-CoV2, Acute Respiratory Distress Syndrome
Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)
*At this time, we are only enrolling at Houston Methodist Hospital (HMH)/Baylor College of Medicine (BCM) and are not shipping cells outside of BCM/HMH.* This is a study for patients who have respiratory infection caused by…
- Conditions
- Sars-CoV2, Acute Respiratory Distress Syndrome, COVID-19
- Trial name
- NCT04345601
- Testing
- Mesenchymal Stromal Cells, Supportive Care
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Baylor College of Medicine
Covid-19, SARS-CoV2
Efficacy and Safety of BIO101 in the Prevention of Respiratory Deterioration in Hospitalized COVID-19 Patients
The COVA clinical study is a global multicentric, double-blind, placebo-controlled, group sequential and adaptive 2 parts phase 2-3 study targeting in participants with SARS-CoV-2 pneumonia.
- Trial name
- COVA (NCT04472728)
- Testing
- BIO101
- Where
- 22 sites in United States, Belgium and 3 more
- Volunteers
- 238 people
- Sponsor
- Biophytis
Sars-CoV2, Serum; Disease
Serological Response to SARS-Cov-2 Virus in Personnel of the Institut Bergonié in the Context of the COVID-19 Pandemic
The question of the immune response of the population, particularly of professional populations in contact with vulnerable populations (such as those with chronic conditions such as cancer), is an important issue.
- Trial name
- PRO-SERO-COV (NCT04426006)
- Testing
- PRO-SERO-COV
- Where
- France
- Volunteers
- 526 people, healthy volunteers welcome
- Sponsor
- Institut Bergonié
COVID, Severe Acute Respiratory Syndrome
LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
To evaluate the proportion of subjects alive and free of respiratory failure (e.g. need for non-invasive or invasive mechanical ventilation, high flow oxygen, or ECMO) and free of the need for continued renal replacement therapy…
- Conditions
- COVID, Severe Acute Respiratory Syndrome, Sars-CoV2, Acute Kidney Injury
- Trial name
- NCT04402957
- Testing
- LSALT peptide
- Where
- 7 sites in United States, Canada and 1 more
- Volunteers
- 61 people
- Sponsor
- Arch Biopartners Inc.
Solid Tumor, Sars-CoV2
Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19
This study is for patients that are hospitalized for Coronavirus Disease 2019 (COVID-19). The purpose of this study is to see whether neutralizing interleukin-8 (IL-8) with BMS-986253 can help improve the health condition of…
- Conditions
- Solid Tumor, Sars-CoV2, Hematological Malignancy
- Trial name
- NCT04347226
- Testing
- BMS-986253
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Columbia University
COVID-19, SARS-CoV2 Infection
International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response
The overarching goal of the Master Protocol is to find effective strategies for inpatient management of patients with COVID-19. Therapeutic goals for patients hospitalized for COVID-19 include hastening recovery and preventing…
- Conditions
- COVID-19, SARS-CoV2 Infection, Coronavirus Infection
- Trial name
- NECTAR (NCT05593770)
- Testing
- Fostamatinib
- Where
- 21 sites in Brazil, Germany and 3 more
- Volunteers
- 28 people
- Sponsor
- NEAT ID Foundation
SARS-CoV2 Infection
Rural Tailored COVID-19 Communication to Promote SARS-CoV-2 Antibody Testing in Saliva
This study seeks to evaluate communication strategies for better encouraging understanding and uptake of salivary SARS-CoV-2 antibody testing among individuals residing in rural Northern Michigan.
- Trial name
- NCT06085547
- Testing
- General SARS-CoV-2 Communication, Rural-Targeted SARS-CoV-2 Communication
- Where
- United States
- Volunteers
- 264 people, healthy volunteers welcome
- Sponsor
- Michigan State University
Sars-Cov2 Antibodies in Children and Adolescents Living With HIV
European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) SARS-CoV-2 Antibody Study Protocol. Covid-19
Scientific knowledge about the COVID-19 pandemic and the virus that is causing it (SARS-CoV-2) is developing rapidly, and the investigators have a clearer idea of the population groups who are at higher risk of becoming infected…
- Trial name
- SARS-Cov2 (NCT04726137)
- Where
- 7 sites in Belgium, Greece and 4 more
- Volunteers
- 906 people
- Sponsor
- PENTA Foundation
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection
Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients
This study is designed to test the efficacy and safety of combinations of two well-understood agents - famotidine and celecoxib.
- Conditions
- 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection
- Trial name
- NCT05077969
- Testing
- Famotidine, Celecoxib
- Where
- 15 sites in United States
- Volunteers
- 4 people
- Sponsor
- Leidos Life Sciences
SARS-CoV2 Infection
Culturally-Targeted COVID-19 Communication and SARS-CoV-2 Antibody Testing Evaluation and Uptake
This disparities-focused study seeks to evaluate communication strategies for better encouraging understanding and uptake of salivary SARS-CoV-2 antibody testing among African Americans residing in Flint, Michigan.
- Trial name
- NCT04957082
- Testing
- Culturally Targeted SARS-CoV-2 Communication, General SARS-CoV-2 Communication
- Where
- United States
- Volunteers
- 666 people, healthy volunteers welcome
- Sponsor
- Michigan State University
COVID-19, Coronavirus
Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19
This is a phase 2, single or multi-center, randomized, double-blind placebo-controlled study to evaluate the safety and efficacy of Rayaldee (CTAP101 Capsules) to treat adult subjects with mild to moderate COVID-19 who test…
- Conditions
- COVID-19, Coronavirus, SARS-CoV2 Infection
- Trial name
- NCT04551911
- Testing
- Rayaldee
- Where
- 10 sites in United States
- Volunteers
- 171 people
- Sponsor
- OPKO Health, Inc.
Sars-CoV2
Rhu-pGSN for Severe Covid-19 Pneumonia
Study Objectives: Primary To assess the efficacy (survival without organ failure on Day 14) of three doses of rhu-pGSN administered intravenously (IV) plus standard of care (SOC) to hospitalized subjects with a primary diagnosis…
- Trial name
- NCT04358406
- Testing
- Recombinant human plasma gelsolin (Rhu-pGSN)
- Where
- 3 sites in Romania, Spain
- Volunteers
- 64 people
- Sponsor
- BioAegis Therapeutics Inc.
SARS-CoV2 Infection
Rutgers Pilot for PREDICT- Patient LAB Test
A pilot study was initiated to assess feasibility of testing asymptomatic dental patients presenting to the Oral Medicine Clinic at Rutgers School of Dental Medicine for SARS-CoV-2 viral RNA using an FDA approved RT-PCR test for…
- Trial name
- NCT05607043
- Testing
- Testing for SARS CoV2 RNA
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
SARS-CoV2 Infection
Rutgers Pilot for Dental Health Care Worker SARS-CoV-2 Testing
10 asymptomatic DHCWs in the Oral Medicine clinic, Rutgers School of Dental Medicine, with no history of documented COVID-19 infection or viral exposure, were enrolled in a study that interrogated DHCWs' perceptions of safety and…
- Trial name
- PREDICT-DHCW (NCT05607147)
- Testing
- Testing for SARS CoV2 Antigen and Antibody
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
SARS-CoV2 Infection, COVID-19
COVID-19 MP Biomedicals SARS-CoV-2 Ag OTC: Clinical Evaluation
SARS-CoV-2 rapid antigen over the counter clinical performance evaluation
- Trial name
- NCT05584176
- Testing
- iCura COVID-19 Antigen Rapid Home Test, RT-PCR Test
- Where
- 4 sites in United States
- Volunteers
- 332 people, healthy volunteers welcome
- Sponsor
- MP Biomedicals, LLC
Covid19, SARS-CoV2 Infection
SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine
The purpose of this study is to evaluate the safety and efficacy of mRNA COVID-19 vaccines in: People with prior COVID-19 (SARS-CoV-2 infection) who were in the ACTIV-2/A5401 study.
- Trial name
- NCT04952402
- Testing
- Study-provided Moderna mRNA-1273 COVID-19 vaccine, Community-provided Moderna mRNA-1273 COVID-19 Vaccine, Community-Provided Pfizer-BioNTech BNT162b2 COVID-19 Vaccine
- Where
- 6 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID, Sars-CoV2
Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)
This clinical trial will enroll participants that have pneumonia caused by the COVID-19 virus. During the study patients will receive 7 to up to 14 days of defibrotide.
- Conditions
- COVID, Sars-CoV2, COVID-19, Acute Respiratory Distress Syndrome
- Trial name
- NCT04530604
- Testing
- Defibrotide
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Gregory Yanik
Sars-CoV2, Covid-19
Mobile Health Study and Enhanced Symptom Monitoring in COVID-19 Cancer Patients
The established Insight(TM) mHealth Platform, a component of the Stephenson Cancer Center (SCC) mHealth Shared Resource will be used to create the "Symptom Tracker" app.
- Trial name
- NCT04397614
- Testing
- mHealth Assessments
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- University of Oklahoma
Covid19, SARS-CoV2 Infection
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
The primary aim of the proposed research is to test the role of a newly developed reusable form-fitting fabric mask in reducing the spread of COVID-19 in a community setting comprising undergraduate students living in dormitories…
- Trial name
- NCT04979858
- Testing
- Focal Mask
- Where
- United States
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Georgia Institute of Technology
COVID-19, Sars-CoV2
Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients
The purpose of this study assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms up to 14 days after the onset of initial symptoms.
- Trial name
- CAPRI (NCT04421404)
- Testing
- COVID-19 Convalescent Plasma (CCP)
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- Priscilla Hsue, MD